ROSEN, A LEADING NATIONAL FIRM, Encourages Allarity Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALLR

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Allarity Therapeutics, Inc. securities between May 17, 2022, and July 19, 2024, of the upcoming lead plaintiff deadline on November 12, 2024, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Allarity securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 12, 2024 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Allarity made false and misleading statements regarding its drug candidate Dovitinib, overstating its regulatory prospects and engaging in improper conduct related to its new drug application [4]. - The misconduct allegedly led to increased risks of regulatory scrutiny and enforcement actions, resulting in significant legal and reputational harm to Allarity [4]. - Following the announcement of an investigation into Allarity's conduct, the company downplayed the likelihood of enforcement actions, which the lawsuit claims caused investor damages when the truth was revealed [4].